H.R. 9972, Medicare Payment Floor & Domestic-Sourcing Mandate. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
H.R. 9972 · Mixed
What it does
This bill creates a new Medicare payment category for skin substitute products (cellular or tissue-based wound treatments) from 2027–2030, setting a fixed reimbursement rate of $457 per square centimeter and requiring products to be domestically sourced, harvested, and manufactured. It imposes strict oversight on providers—including prepayment review, prior authorization, and certification requirements—and bars Medicare from denying coverage based solely on clinical evidence during 2027. The bill benefits wound-care manufacturers and certified providers who meet domestic-sourcing rules, while imposing compliance costs and payment floors on the industry.
The analysis names skin substitute product manufacturers (domestic only) — and 2 more groups — among the beneficiaries.
The trade-off
The $457/sq cm payment rate and $342.75/sq cm cost floor are set by statute without reference to actual production costs, clinical outcomes, or competitive pricing—locking in margins for 4 years and creating a de facto price floor that may inflate Medicare spending.
The analysis put a high warning level on this bill. Transparency scores 55%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Pete Sessions.